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Introduction: Cerebral ischemia is the third leading cause of death and the primary cause of permanent 
disability worldwide. Atorvastatin is a promising drug with neuroprotective effects that may be useful for 
the treatment of stroke. However, the effects of atorvastatin on specific neuronal populations within the 
nigrostriatal system following cerebral ischemia are unknown. 
Objective: To evaluate the effects of atorvastatin on dopaminergic and GABAergic neuronal populations 
in exofocal brain regions in a model of transient occlusion of the middle cerebral artery. 
Materials and methods: Twenty-eight male eight-week-old Wistar rats were used in this study. 
Both sham and ischemic rats were treated with atorvastatin (10 mg/kg) or carboxymethylcellulose 
(placebo) by gavage at 6, 24, 48 and 72 hours post-reperfusion. We analyzed the immunoreactivity 
of glutamic acid decarboxylase and tyrosine hydroxylase in the globus pallidus, caudate putamen 
and substantia nigra. 
Results: We observed neurological damage and cell loss in the caudate putamen following ischemia. 
We also found an increase in tyrosine hydroxylase immunoreactivity in the medial globus pallidus and 
substantia nigra reticulata, as well as a decrease in glutamic acid decarboxylase immunoreactivity in 
the lateral globus pallidus in ischemic animals treated with a placebo. However, atorvastatin treatment 
was able to reverse these effects, significantly decreasing tyrosine hydroxylase levels in the medial 
globus pallidus and substantia nigra reticulata and significantly increasing glutamic acid decarboxylase 
levels in the lateral globus pallidus. 
Conclusion: Our data suggest that post-ischemia treatment with atorvastatin can have neuro-
protective effects in exofocal regions far from the ischemic core by modulating the GABAergic and 
dopaminergic neuronal populations in the nigrostriatal system, which could be useful for preventing 
neurological disorders.
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La atorvastatina protege las neuronas gabérgicas y dopaminérgicas del sistema nigroestriatal 
en un modelo experimental de isquemia cerebral focal transitoria en ratas
Introducción. La isquemia cerebral es la tercera causa de muerte y la primera de discapacidad 
permanente en el mundo. La atorvastatina es un fármaco neuroprotector prometedor para el tratamiento 
de la apoplejía; sin embargo, su acción sobre las poblaciones neuronales del sistema nigroestriatal 
después de la isquemia aún se desconoce.
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Objetivo. Evaluar el efecto de la atorvastatina sobre poblaciones gabérgicas y dopaminérgicas en 
regiones exofocales en un modelo de oclusión transitoria de la arteria cerebral media. 
Materiales y métodos. Se utilizaron 28 ratas Wistar macho de ocho semanas de edad. Los ejemplares 
con isquemia simulada y los ejemplares sometidos a isquemia fueron tratados con atorvastatina (10 
mg/kg) y carboximetilcelulosa (placebo) administrados por medio de sonda a las 6, 24, 48 y 72 horas 
después de la reperfusión. Se analizó la inmunorreacción de la descarboxilasa del ácido glutámico y 
de la tirosina hidroxilasa en el globo pálido, el putamen caudado y la sustancia negra. 
Resultados. Los datos confirmaron el daño neurológico y la pérdida celular en el putamen caudado. 
Se incrementó la inmunorreacción de la tirosina hidroxilasa en el globo pálido medial y la sustancia 
negra pars reticulata, disminuyendo la inmunorreacción de la descarboxilasa del ácido glutámico en el 
globo pálido lateral de los animales isquémicos tratados con placebo; sin embargo, el tratamiento con 
atorvastatina pudo revertirla, lo que logró una disminución  significativa de la tirosina hidroxilasa en el 
globo pálido medial y la sustancia negra pars reticulata y aumentando los niveles de descarboxilasa 
del ácido glutámico en el globo pálido lateral. 
Conclusión. Nuestros datos sugieren que la atorvastatina en el tratamiento posterior a la isquemia 
ejerce neuroprotección en las zonas exofocales, modulando las poblaciones neuronales gabérgicas y 
dopaminérgicas del sistema nigroestriatal, lo que podría prevenir trastornos neurológicos.
Palabras clave: neuronas gabérgicas, neuronas dopaminérgicas, isquemia encefálica, modelos 
animales, ratas. 
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Cerebrovascular disease is the third leading cause 
of death worldwide and the leading cause of 
permanent disability in adults. This disease 
causes motor and sensory sequelae that affect 
both the quality of life and longevity of patients and 
negatively impact the economic and productive 
sectors (1,2).
Ischemic strokes are caused by arterial occlusions, 
and the damaged regions are characterized by a 
central necrotic core and a surrounding penumbral 
area. The latter tissue can recover from the 
physiological stress of a nearby ischemia, and 
these areas are generally the targets for stroke 
therapies (3). Changes can also occur in tissues 
removed from the site of physical injury. These 
are known as exofocal changes, and they may be 
responsible for some of the clinical manifestations 
that are not directly related to the ischemic 
core injury, including behavioral, emotional and 
cognitive disorders that can appear weeks or 
months after the ischemic injury (4).
Exofocal changes have been observed in 
components of the basal ganglia, including the 
caudate putamen (CPu), globus pallidus (Gp) and 
substantia nigra (SN), which often show changes 
near the middle cerebral artery (MCA) following 
ischemic stroke. The globus pallidus is primarily 
composed of GABAergic neurons and is located 
near the putamen, immediately outside the internal 
capsule; this region can be further divided into 
the globus pallidus lateral (GpL) and the globus 
pallidus medial (GpM) (5). The SN is located below 
the thalamus and is divided into two functionally 
different structures: the pars reticulata (SNr) and 
the pars compacta (SNc). The SNr is composed 
of GABAergic-type fusiform neurons and is 
innervated by Gp; the SNr sends its axons to the 
thalamus, where it complements related circuits 
with sensorimotor and behavioral functions. The 
SNc is composed of dopaminergic neurons and 
innervates the caudate putamen (CPu) nucleus, 
where, among other things, it exerts a modulatory 
effect on motor functions (6).
With the aim of reducing the consequences 
of ischemic events, several pharmacological 
strategies have been elucidated and applied in 
clinical studies. For example, statins – which were 
first identified as molecules that inhibit the enzyme 
3-hydroxymethylglutaryl coenzyme A (HMG-
CoA) – are known to have pleiotropic effects 
independent of their ability to inhibit cholesterol 
synthesis. In particular, statins can also enable 
angiogenesis and synaptogenesis, increase blood 
flow and inhibit the formation of thrombosis and 
atheromatous plaques (7-9). One of the most 
commonly used statins, atorvastatin (ATV), has 
been shown to reduce infarct volume and improve 
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neurological deficits in a rat cerebral ischemia 
model (10). In addition, it is known that activation 
of the pro-survival PI3 kinase pathway decreases 
excitotoxicity, modulates platelet activity and 
inhibits the inflammatory response in ischemic 
settings (11,12). In this study, we focused on the 
poorly studied exofocal areas, determining the 
effect of ATV on GABAergic and dopaminergic 
neuronal populations of the nigrostriatal system 
in a model of transient focal cerebral ischemia in 
Wistar rats.
Materials and methods
Animals
Male Wistar albino rats were obtained from an in-
house, pathogen-free colony at the vivarium of SIU, 
University of Antioquia, Medellín, Colombia. Rats 
were maintained under a 12:12-h dark:light cycle 
and given food and water ad libitum. Animals were 
handled in accordance with Colombian standards 
(Law 84/1989 and Resolution 8430/1993) and 
European Union guidelines (86/609/EEC). Special 
care was taken to minimize animal suffering and to 
reduce the number of animals used in these exper-
iments. In particular, 2.5-month-old rats weighing 
between 220-250 g were used in these studies.
Surgical procedure
MCAO and reperfusion protocols were carried 
out as described previously (13), with minor 
modifications. Briefly, animals were anesthetized 
with an i.p. mixture of ketamine (60 mg/kg) 
and xylazine (5 mg/kg) as well as s.c. atropine 
(0.01 mg/kg). The right common carotid artery 
was exposed and dissected through a medial 
cervical approach. The external and internal 
carotid arteries (ECA and ICA, respectively) 
were exposed, and the first arterial branches 
were cauterized by electrocoagulation (Aaron 
bipolar cautery). For the following steps, a 4-0 
nylon monofilament suture (Ethicon, Johnson & 
Johnson) was used, which was pretreated with 
poly-L-lysine (0.1% in de-ionized water), rounded 
at its tip with a heat treatment and sterilized with UV 
radiation. The filament was inserted into the ICA 
from the ECA in order to occlude the right middle 
cerebral artery. The suture was removed after 
60 minutes of occlusion to allow for reperfusion. 
Finally, the cervical wound was closed along one 
plane. Sham animals were subjected to the same 
procedures but the filament was not introduced 
into the artery. All animals were sacrificed 78 
hours after reperfusion.
Administration of atorvastatin 
One ischemic group of animals received 10 mg/
kg oral doses of calcic atorvastatin (Atorlip®-20, 
Lafrancol), which were administered using a gastric 
esophageal catheter. Treatment was repeated for 3 
consecutive days following ischemia. The first dose 
was administered 6 hours post-reperfusion and 
again after 24, 48 and 72 hours. The other ischemic 
group received carboxymethylcellulose (CMC) as 
a placebo, which was delivered at the same time 
and with the same frequency as the experimental 
drug. Unoperated rats in the control groups (sham) 
received either ATV or CMC under the same 
conditions as the experimental ischemic groups.
Recovery and neurological evaluation
Following surgery, the animals were taken to their 
home cages to recover from anesthesia. Using 
the neurological test described by Bederson, 
et al., 1986 (14), neurological evaluations were 
performed six hours after the ischemia/reperfusion 
procedure and again after 24, 48 and 72 hours. 
This test is scored on a scale from 0 to 6: 0 = no 
spontaneous movement; 1 = spontaneous circular 
movements; 2 = circular movements if held by the 
tail; 3 = circular movements if lifted and held by 
the tail; 4 = reduced resistance to lateral pressure; 
5 = flexion at one or both forelimbs; 6 = normal 
extension of both forelimbs when lifted. The 
animals were also tested for other neurological 
disorders not accounted for in the above scale, 
including balance tests along both the vertical and 
horizontal planes, tests of spatial perception, and 
tests of corneal, visual, palpebral and acoustic 
reflexes (13).
Histology
Six hours after the final treatment dose, the animals 
were anesthetized intraperitoneally with a mixture 
of sodium pentobarbital (60 mg/kg) and xylazine (10 
mg/kg) and perfused with 4% paraformaldehyde 
in saline (0.1 M phosphate buffer [PBS], pH 7.4). 
The brains were then carefully removed and post-
fixed with 4% paraformaldehyde at 4 °C for 48 
hours. The brains were divided into right and left 
hemispheres and sectioned using a vibratome 
(Leica Microsystems 1000S VT) into 50-micron 
slices from lateral -0.18 to 4.32 mm, using the 
Paxinos stereotaxic atlas for rats as a reference 
(15). Lateral sections (from 2.4 to 2.9 mm) were 
evaluated by Nissl staining with 1% toluidine blue. 
The sections were dehydrated in alcohol, treated 
with xylenes and sealed with Canada balsam.
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Immunohistochemistry
Sections were first treated with methanol (50% 
v/v) and hydrogen peroxide (30% v/v) in 0.1 M 
PBS (pH 7.4) for 20 minutes to inhibit endogenous 
peroxidase activity. Next, the sections were washed 
three times with 0.1 M PBS, and nonspecific 
binding sites were blocked for 1 hour with a pre-
incubation solution consisting of 0.1 M PBS with 
BSA (1%) and Triton X-100 (0.3% v/v).
The sections were then incubated overnight at 4 
°C with the primary antibodies, which were diluted 
in incubation solution (0.3% BSA and 0.3% v/v 
Triton X-100 in 0.1 M PBS). Anti-TH (1:1000, 
mouse monoclonal LNC1-MAB318, Chemicon 
International, Inc.) was used to detect the enzyme 
tyrosine hydroxylase, and anti-GAD 65/67 (1:1000, 
polyclonal rabbit G5163; Sigma) was used to detect 
glutamic acid decarboxylase. The next day, the 
sections were washed for 5 minutes in 0.1 M PBS 
and then incubated with the appropriate secondary 
antibodies (1:250 biotin-conjugated goat anti-rabbit 
IgG (H+L) 31822 or 1:250 biotin-conjugated goat 
anti-mouse IgG (H+L) 31800; Pierce), depending 
on the host in which primary antibody was prepared, 
for one hour at room temperature.
After three washes with 0.1 M PBS, the tissues 
were incubated with avidin-biotin complex (1:250 
reagent A and B, ABC Standard Peroxidase 
Staining Kit, 32020; Pierce) for 1 hour. Once 
excess complex was removed, three more washes 
were performed, and the sections were stained 
with diaminobenzidine (DAB). Subsequently, the 
sections were dehydrated with alcohol, cleared 
with xylenes and sealed with Canada balsam. 
Quantification of immunoreactivity in the areas 
tested was determined using a 10× objective for 
GP and SNr. Photomicrographs of the histological 
and immunohistochemical assays were also 
analyzed using the ImageJ 1.44 software program 
(NIH, USA). Controls carried out without primary 
antibodies did not result in immunoreactivity.
Western blotting analysis
Animals were sacrificed by decapitation and their 
brains were quickly removed. The globus pallidus 
and contralateral and ipsilateral substantia nigra 
were dissected and frozen at -70 °C for later analysis. 
The tissues were dissected and homogenized in 
lysis buffer containing 150 mM NaCl, 20 mM Tris 
(pH 7.4), 10% glycerol, 1 mM EDTA, 1% NP40, 100 
μM phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin 
and leupeptin (Sigma) and 100 μM orthovanadate.
Proteins were separated using sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (10% 
SDS-PAGE) and the Mini-Protean system (Bio-
Rad, Hercules, CA) with a wide-range molecular 
weight standard (Bio-Rad). Each lane was loaded 
with 10 mg protein and a buffer containing 0.375 
M Tris (pH 6.8), 50% glycerol, 10% SDS, 0.5 M 
DTT and 0.002% bromophenol blue. The samples 
were heated to 95 °C for 5 minutes before loading 
on the gel. Following electrophoresis, the proteins 
were transferred to nitrocellulose membranes 
(Amersham) using an Electrophoretic Transfer 
System (Mini Trans-Blot Electrophoretic Transfer 
Cell) at 300 mA for 1 hour. The membranes were 
washed with TTBS (20 mM Tris-HCl (pH 7.5), 500 
mM NaCl, Tris-buffered saline (pH 7.4) and 0.05% 
Tween-20) and 5% lyophilized skimmed milk powder 
for 1 hour; TTBS was used for all subsequent 
washes and incubations. The membranes were 
then incubated overnight with the following primary 
antibodies: anti-TH (1:1000 mouse monoclonal 
LNC1-MAB318; Chemicon International Inc.) and 
anti-GAD 65/67 (1:1000 rabbit polyclonal G5163; 
Sigma); an anti-actin antibody (1:1000 mouse 
monoclonal AC-40-A3853; Sigma) was used as a 
loading control. Next, the membranes were washed 
and incubated for 1 hour at room temperature 
with an appropriate secondary antibody (1:250 
peroxidase-conjugated anti-rabbit or anti-mouse 
IgG). Finally, the membranes were washed several 
more times, and bound antibodies were detected 
using the Enhanced Chemiluminescence System 
(ECL) for Western Blotting (34080; Thermo 
Scientific, Rockford, IL, USA) and exposure on 
autoradiographic film (Hyperfilm ECL; Amersham; 
or RP2 plus films; AGFA). The films were analyzed 
by densitometry using the Bio Rad Quantity One 
software program, version 4.6 (Umax Powerlook 
2100XL Scanner; Bio Rad).
Statistical analysis
Each experimental group for neurological evalua-
tion consisted of 12 animals, whereas the groups 
for histological and biochemical analysis consisted 
of 3 and 4 animals, respectively. The InfoStat 
program (version 2008) was used to perform tests 
for normality and homogeneity of the variances. 
Parametric data were analyzed using ANOVA 
and Tukey’s test as a post hoc test of multiple 
comparison between treatment means. For data 
with non-homogeneous variances, we used a 
Kruskal-Wallis nonparametric ANOVA test to 
determine any significant differences between 
independent groups. Analyses were carried out 
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using the GraphPad Prism 5.0 software program. 
Differences with p values less than 0.05 were 
considered to be significant.
Results
ATV protects against motor impairment 
following cerebral ischemia.
A neurological test was developed for analyzing 
the recovery of animals treated with ATV following 
focal cerebral ischemia. We observed sensory and 
motor deterioration in the ischemic rats 6 hours 
after injury (2.7/6.0). Slight improvements were 
observed in the ATV-treated animals by 24 and 48 
hours post-ischemia compared with the placebo 
group. However, by 72 hours post-ischemia, the 
ATV-treated animals had shown significant recovery 
(5.6/6.0) compared with the placebo group (4.2/6.0) 
(P<0.001) (figure 1A). This finding is consistent with 
previous results from our lab showing that ATV can 
mitigate the loss of NeuN and MAP2 staining within 
the cerebral cortex and hippocampus following 
cerebral ischemia (16,17). It has been demonstrated 
that focus areas suffer cell death, although is poorly 
studied exofocal areas that are represented in 
figure 1B, being the interest of the present study. 
Ischemia-induced injuries near the MCA, 
such as cellular alterations in the GpM and 
increased immunoreactivity in the TH, can be 
reversed by ATV.
Tyrosine hydroxylase catalyzes the rate-limiting 
step in the synthesis of dopamine – an important 
neurotransmitter for motor control and reward – 
motivated behaviors (18) - and this enzyme has 
been shown to be modulated by ischemia. We 
did not observe any changes in TH levels in the 
GpL by immunohistochemistry (figure 2a-A-D, b). 
Although we did observe that Gp total lysates from 
ischemic animals had increased TH protein levels 
compared with controls (P≤0.05); furthermore, we 
found that TH levels were reversed in the ischemic 
animals by the ATV-treatment similar to those in 
the controls (figure 2e). These biochemical findings 
were supported by histological experiments in the 
GpM that showed increased TH immunoreactivity 
and altered cytoarchitecture (figure 2a-G,c) in the 
untreated ischemic animals (P≤0.001) compared 
with the sham+placebo (figure 2a-E,c) and sham+ 
ATV (figure 2a-F,c) groups. However, the ATV-
treated ischemic animals showed decreased TH 
immunoreactivity (P≤0.01) (figure 2a-H,c) and a 
cellular organization similar to the control animals.
ATV decreases TH immunoreactivity in the 
SNr and promotes fiber arborization following 
ischemia in the area of the MCA.
We observed an increase in TH immunoreactivity 
in the SNr of ischemic animals (P≤0.01) (figure 
2a-K,d), whereas ATV-treated animals showed 
a significant decrease in TH staining (P≤0.05). 
Furthermore, we found a more abundant fiber 
arborization pattern (figure 2a-L,d) compared with 
the sham-placebo control (figure 2a-I,d) and ATV 
control groups (figure 2a-J,d). These findings were 
consistent with TH protein levels in the SN total 
protein lysates as determined by Western blotting 
Figure 1. Neurological evaluation following focal cerebral ischemia A. ATV significantly reduces neurological deficits in a tMCAO 
model 48 and 72 hours after reperfusion (P<0.001) compared with the ischemic placebo group. Arbitrary values (AV) from 0 to 6 
were assigned based on the neurological responses to each test (n=12/group). B. Nigrostriatal system; GpL (lateral globus pallidus), 
GPM (medial globus pallidus) and SN (substantia nigra) are highlighted in red. S+P: sham+placebo, S+A: sham+atorvastatin, I+P: 
ischemia+placebo, I+A: ischemia+atorvastatin. ***P<0,001. 
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Figure 2. ATV treatment modulates dopaminergic populations in the substantia nigra (SN) and globus pallidus (Gp). Representative 
photomicrographs of TH immunohistochemical signals in the following regions: a) A-D globus pallidus lateral (GpL); a) E-H globus 
pallidus medial (GpM); and a) I-L SN pars reticulata (SNr). Magnification, 10X. Scale bar, 50 μm. Insert, 40X. Signal intensity is shown 
in relative units (RU) with statistical significance relative to GpL (b), GpM (c) and SNr (d). Representative bands and densitometric 
quantifications of TH levels in the GP (e) and SN (f) as determined by Western blotting analysis; actin was used as a loading control. 
S+P: sham+placebo, S+A: sham+atorvastatin, I+P: ischemia+placebo, I+A: ischemia+atorvastatin. *p≤0.05, **p≤0.01, *** p=0.001
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analysis, which showed that ATV treatment could 
significantly inhibit the upregulation of TH induced 
by ischemia (P≤0.05) (figure 2f).
ATV rescues the loss of GAD 65/67 
immunoreactivity in the GpL near the MCA 
following ischemia.
It is well known that glutamic acid decarboxylase 
(GAD) is one of the rate-limiting enzymes in GABA 
synthesis and that it can be used as a reliable 
marker for inhibitory interneurons (19). GAD65 
plays an important role in the local control of 
GABA synthesis at synapses, whereas GAD67 
is responsible for maintaining GABA at baseline 
levels for use as both a neurotransmitter and a 
metabolite (20). GAD 65/67 immunoreactivity was 
significantly decreased within the GpL by 78 hours 
post-injury (P≤0.05) (figure 3a-C,b), a phenomenon 
that could be rescued with ATV treatment (P≤0.05) 
(figure 3a-D,b) to levels similar to those observed 
in the controls (figure 3a-A-B,b). No changes were 
observed in the GpM (figure 3-E-H, c). We also 
note that no significant differences in GAD 65/67 
protein levels could be detected between Gp total 
lysates from injured and control samples (figure 
3e), although it is likely that such differences 
were lost when the GpL and GpM proteins were 
pooled. In addition, no changes in GAD 65/67 
immunoreactivity were detected within the SNr 
by immunohistochemistry (figure 3a-I-L,d) or by 
Western blotting analysis (figure 3-f).
Discussion
Our findings demonstrate that the expression levels 
of specific enzymes involved in the synthesis of 
the neurotransmitters dopamine and GABA within 
certain exofocal brain regions, as well as in the 
nigrostriatal system, are affected by focal cerebral 
ischemia, and they also suggest that these changes 
can be reversed by post-ischemia ATV treatment. 
It appears that excitotoxic conditions resulted in 
increased immunoreactivity in TH-positive neurons 
within the GpM and SNr, as well as a decrease 
in the GABAergic cell population (GAD 65/67+) 
within the GpL. Strikingly, ATV treatment could 
successfully block the negative effects of this 
cellular environment, leading to an increase in the 
GABAergic neuronal population within the GpL 
and blocking the increases in TH immunoreactivity 
within the GpM and SNr. These observations are 
supported by previous reports where TH staining 
increased in the SNc and striatum in injured rats (21). 
Also, considering that SNr and SNc are functionally 
depending and these project to the striatum (22), 
could mean an up-regulation of dopaminergic 
neurotransmission in a tissue-specific manner at 
the nigrostriatal system depending of the brain 
injury. Also, these findings suggest that ATV helps 
restore equilibrium in tissues affected by ischemia 
and that ATV reduces the expression of TH in the 
dopaminergic neurons of the SNr while maintaining 
projections to the striatum. These results support 
a protective role for statins following stroke, and 
they are consistent with our previous description 
of the induction of survival pathways and synaptic 
connectivity under post-ischemic conditions by ATV 
(7,9). Furthermore, these data suggest that statins 
can block excitotoxic events in a tissue-specific 
manner. In particular, ATV may act to silence an 
increase in inhibitory signals coming from the GpL 
that control the excitatory efferents to the SNr, which 
are a product of exofocal phenomena following 
ischemia, generating a protective modulation 
of protein levels within the nigrostriatal system, 
which may be related to neurological recovery. 
It is important to emphasize that these types of 
neurological deficits caused by cerebral ischemia 
have been correlated with injury severity and size 
in experimental models (13,23,24).
Previous studies from our group and others 
demonstrated that ATV treatment (10 mg/kg) can 
significantly improve neurological scores at 48 and 
72 hours post-ischemia (9). This was also found 
to be true for pravastatin (1 mg/kg) 5 days after 
the induction of cerebral ischemia in the vicinity 
of the MCA (8), as well as with other statins and 
neuroprotective agents (25,26).
In the present study, GAD 65/67 immunoreactivity 
was dramatically decreased in the GpL following 
focal ischemia, which was indicative of a loss in 
either the activity or number of GABAergic neurons 
within the GpL. This specific effect has not been 
reported before, although it has been reported 
that deficiencies in GABA production can induce 
neuronal death (19). Furthermore, changes in 
GAD 67 enzyme levels have been described in the 
cerebral cortex following ischemia; in particular, 
GAD 67 levels were shown to increase after 
12 hours of reperfusion and then progressively 
decrease over the next 4 days (19). Nishino, et al., 
(27) reported a 50% decrease in pallidal GABA in 
ischemic animals compared with control animals, as 
determined using microdialysis analysis. It is impor-
tant to emphasize that during an ischemic stroke, 
glutamatergic activity increases, which decreases 
the endogenous synthesis and release of GABA, 
leading to reduced GABAergic transmission. As 
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Figure 3. ATV treatment modulates GABAergic populations in the globus pallidus (Gp). Representative photomicrographs of GAD 
65/67 immunohistochemical signals in the following regions: a) A-D globus pallidus lateral (GpL); a) E-H globus pallidus medial 
(GpM), and a) I-L SN pars reticulata (SNr). Magnification, 10X. Scale bar, 50 μm. Insert, 40X. Signal intensity is shown in relative units 
(RU) with statistical significance relative to GpL (b), GpM (c) and SNr (d). Representative bands and densitometric quantifications 
of GAD 65/67 levels in the GP (e) and SN (f) as determined by Western blotting analysis; actin was used as a loading control. S+P: 
sham+placebo, S+A: sham+atorvastatin, I+P: ischemia+placebo, I+A: ischemia+atorvastatin. *p≤0.05, **p≤0.01, ***p=0.001
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glutamatergic and GABAergic transmissions have 
antagonistic effects, increases in GABAergic activity 
in an ischemic setting can compensate for the excess 
glutamatergic signaling, leading to decreased cell 
death; conversely, decreased GABAergic signaling 
in this setting promotes cell death (28,29). The 
findings in this study were also consistent with our 
previous observations of increased neuronal death 
and decreased Bcl-2 levels in the SNr following an 
ischemic event (20). In addition, our data show that 
post-ischemia ATV treatment increases GAD 65/67 
immunoreactivity, which may suggest a potential 
mechanism for the observed neuroprotective effects 
by enhancing GABAergic transmission, which is 
consistent with other studies demonstrating that 
inducing certain inhibitory conditions can be used 
to control cell death following ischemia (28,30-33).
The observed reduction in TH immunoreactivity 
in the exofocal area of the GpM following ATV 
treatment has not been previously described. 
Existing data point to increased levels of dopa-
mine during ischemia (34,35), particularly in the 
neostriatum (18,36-39). For example, substantial 
increases in dopamine levels in this brain region 
were reported following 10 minutes of arterial 
occlusion, which then returned to baseline levels 
after 60 minutes (40). However, other studies have 
reported that dopamine protects neurons against 
glutamate-induced excitotoxicity (37) and that 
dopamine levels are reduced following ischemia 
(38-40). In addition, it has been shown that some 
experimental conditions can lead to increased TH 
levels in the striatum (21), suggesting the exist-
ence of tissue-specific modulation. The observed 
increase in dopamine levels in the SNr following 
MCA ischemia was similar to the modulation 
observed in the GpM, which could be due to the 
structural proximity and similar functions of these 
two brain regions. It is important to stress that 
changes in dopamine production and release 
during ischemia are potentially harmful to cells. 
However, ATV treatment was able to restore basal 
dopamine levels, suggesting a specific function 
in dopamine synthesis, which is supported by the 
neurological responses and behavioral recovery 
(20,36). On the other hand, we also recorded 
increased TH immunostaining in the GpM of sham 
animals treated with ATV, but these changes were 
not accompanied by neurological or behavioral 
defects. It is possible that these changes were 
balanced out by the weak increase in GAD65/67 
immunoreactivity observed in the GpL and GpM, 
suggesting that neurotransmission may actively 
stimulated by atorvastatin in these areas. It should 
be noted, however, that a recent report indicates that 
ATV has variable effects on membrane transporters 
in the liver (41). Taken together, the ATV-treated 
ischemic animals had better neurological recovery 
and reversed altered neurotransmission signals, 
indicating that ATV can exert neuroprotective effects 
in these areas, even in late ischemic injuries.
Finally, our findings suggest a relationship between 
behavioral deficits and the impairment of GABAergic 
and dopaminergic neuronal populations in specific 
exofocal regions. These regions are involved in 
processing sensorimotor, cognitive and affective 
information, which is consistent with the types 
of pathophysiological conditions that often occur 
following ischemia, such as depression (42,43), 
anxiety, cognitive disorders and other behavioral 
changes (44-46).
In conclusion, atorvastatin plays a neuroprotective 
role in specific exofocal areas affected by ische-
mia through the tissue-specific modulation of 
dopaminergic and GABAergic neuronal populations 
in the nigrostriatal system. These findings will be 
useful for developing novel preclinical therapies 
related to the pathophysiology of exofocal regions 
and help determine therapeutic uses for ATV 
following cerebral ischemia.
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